There is a complex pharmaceutical manufacturing dynamic wherein efforts to repatriate pharmaceutical production to the United States with a goal to increase supply chain security and foster biomedical innovation—paradoxically contribute to higher drug prices.
Pharmaceutical manufacturing involves the industrial-scale production of medications through chemical synthesis, fermentation, or biotechnological processes. As of August 2019, only 28% of API manufacturing facilities supplying the U.S. market were located in the U.S.; the remaining 72% were overseas.
There are three primary types of pharmaceutical manufacturing:
- Primary manufacturing – production of APIs;
- Secondary manufacturing – formulation and dosage creation;
- Tertiary manufacturing – packaging and distribution.
Repatriating these processes aims to reduce vulnerability to global disruptions, as seen during the COVID-19 pandemic. “Reshoring increases resilience, but at a cost,” explains Dr. Andrea Harris, Director of Pharmaceutical Policy at the Brookings Institution. “Domestic facilities face higher regulatory, labor, and environmental compliance costs, which directly impact drug pricing.”
The purpose of reshoring includes safeguarding national health security, ensuring quality control, and stimulating domestic R&D pipelines. However, its efficiency is measured through production scalability, regulatory throughput, and cost per unit—metrics where U.S. facilities often lag behind lower-cost global competitors.
Understanding the Current Landscape
America faces a critical paradox in pharmaceutical production. As highlighted in a recent Real Clear Health analysis, "The United States leads the world in pharmaceutical innovation and drug development, but over 70% of these drugs are manufactured outside the US." This disconnect between innovation and production creates vulnerabilities in our healthcare system and raises important questions about drug accessibility, national security, and economic competitiveness.
The Offshore Reality
The pharmaceutical industry's shift to offshore manufacturing didn't happen overnight. Companies have systematically moved production to countries with lower costs of goods and labor, particularly China and India. While this strategy has helped control drug prices to some degree, it has created significant dependencies that became starkly apparent during recent global health emergencies.
The Cost-Location Dilemma
Pharmaceutical companies currently face an impossible choice: either onshore manufacturing to strengthen supply chain security or maintain offshore production to offer competitive pricing. At present, achieving both objectives simultaneously seems economically unfeasible without significant policy intervention and structural changes to the industry.
Three Pillars for Transformation
1. Streamlining FDA Processes
The drug development process remains one of the most expensive and time-consuming endeavors in modern industry, often requiring decades and hundreds of millions of dollars to bring a single drug to market. The unpredictable nature of FDA reviews adds additional complexity and cost. Several factors compound these challenges:
- Review outcomes can depend heavily on the specific review team's interpretation of regulations
- Only a small percentage of drugs ever reach commercial viability
- Successful drugs must financially cover the development costs of failed candidates
- Regulatory uncertainty discourages innovation and investment
Reducing bureaucracy while maintaining safety standards could significantly lower drug development costs and ultimately consumer prices.
2. Embracing Artificial Intelligence
The pharmaceutical industry has been notably slow to adopt AI technologies, partly due to accuracy concerns and regulatory uncertainty. The recent White House AI Action Plan specifically identifies healthcare as a sector lagging in AI adoption, citing complex regulatory landscapes as a primary barrier.
The potential benefits of AI integration include:
- Accelerated drug discovery: AI can identify promising compounds faster than traditional methods
- Optimized manufacturing processes: Machine learning can improve production efficiency and quality control
- Predictive modeling: AI can better forecast drug interactions and side effects
- Cost reduction: Automation and optimization can significantly reduce production expenses
If regulatory frameworks can adapt to accommodate AI-driven processes, the industry might achieve the seemingly impossible goal of onshoring production while reducing costs.
3. Strategic Financial Incentives
Government intervention through targeted financial incentives could offset the higher costs of domestic manufacturing. Key policy tools include:
- Tariff exemptions: Waiving tariffs on raw materials used in domestic drug production
- Tax benefits: Reducing tax burdens for companies that manufacture pharmaceuticals in the United States
- Investment credits: Providing direct financial support for building and upgrading domestic facilities
- Research grants: Funding innovation in manufacturing technologies that reduce production costs
The National Security Imperative
Supply Chain Vulnerabilities
Recent global events have exposed the risks of depending on foreign nations for essential medications. Supply chain disruptions can leave Americans without access to critical drugs, from antibiotics to cancer treatments. This vulnerability extends beyond public health to national security, as military readiness depends on reliable pharmaceutical supplies.
Building Resilience
Repatriating drug manufacturing isn't just about economics—it's about creating a resilient healthcare system capable of responding to emergencies. Domestic production capacity ensures:
- Continuous supply during global crises
- Quality control and safety oversight
- Rapid response to emerging health threats
- Protection of intellectual property
- Reduced dependence on potentially adversarial nations
The Innovation Ecosystem
Maintaining America's Competitive Edge
The United States has long been the global leader in pharmaceutical innovation, developing breakthrough treatments for previously incurable diseases. This leadership position depends on a complex ecosystem of research universities, biotech startups, major pharmaceutical companies, and regulatory agencies.
The Risk of Stagnation
Without addressing the current challenges, America risks losing its innovation advantage. High development costs and regulatory uncertainty discourage investment in novel therapies, particularly for rare diseases with smaller patient populations. The industry needs confidence that innovation will be rewarded through:
- Predictable regulatory pathways
- Reasonable development timelines
- Fair pricing that reflects research investments
- Protection from unfair foreign competition
The Path Forward
Short-Term Actions
Immediate steps can begin shifting the balance toward domestic production:
- Pilot programs: Test streamlined FDA approval processes for specific drug categories
- AI sandboxes: Create regulatory frameworks for testing AI in pharmaceutical applications
- Emergency stockpiles: Identify critical medications requiring domestic production capacity
- Partnership initiatives: Foster collaboration between government, industry, and academia
Long-Term Vision
The ultimate goal extends beyond simply moving factories back to American soil. Success requires reimagining pharmaceutical manufacturing through:
- Advanced manufacturing technologies that reduce production costs
- Integrated supply chains that source materials domestically when possible
- Workforce development programs that train skilled pharmaceutical workers
- Regional manufacturing hubs that create economies of scale
Balancing Competing Priorities
The Pricing Challenge
While onshoring manufacturing serves national interests, it must not make medications unaffordable for American patients. Achieving this balance requires careful coordination between:
- Insurance coverage policies
- Government purchasing programs
- Competition from generic drugs
- International pricing strategies
Quality and Access
Domestic production must maintain the highest quality standards while ensuring broad access to medications. This means:
- Investing in state-of-the-art facilities
- Implementing rigorous quality control systems
- Creating distribution networks that reach all communities
- Addressing disparities in healthcare access
Conclusion: A National Imperative
Repatriating pharmaceutical manufacturing while maintaining affordable drug prices represents one of the most complex challenges facing American healthcare policy. Success requires coordinated action across multiple fronts: regulatory reform, technological innovation, and strategic financial incentives.
The stakes extend far beyond corporate profits or consumer prices. This is about ensuring America's health security, maintaining our position as the global leader in medical innovation, and guaranteeing that life-saving medications remain accessible to all Americans.
By thoughtfully implementing reforms that reduce development costs, embrace new technologies, and incentivize domestic production, we can achieve what currently seems impossible: bringing drug manufacturing home while making medications more affordable. This transformation won't happen overnight, but with sustained commitment and smart policy choices, America can build a pharmaceutical industry that serves both national security and public health needs for generations to come.
